Laura J Chambers
Overview
Explore the profile of Laura J Chambers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
35
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Piver R, Wagner V, Levine M, Backes F, Chambers L, Cohn D, et al.
Gynecol Oncol Rep
. 2023 Mar;
46:101156.
PMID: 36910448
Objective: Gynecologic cancers are associated with a high risk of venous thromboembolism (VTE). The Khorana score is a validated tool to assess risk of VTE in cancer patients. The purpose...
2.
Wagner V, Piver R, Levine M, Backes F, Chambers L, Cohn D, et al.
Am J Obstet Gynecol
. 2022 Dec;
228(5):555.e1-555.e8.
PMID: 36574873
Background: Uterine cancers are associated with a high risk for venous thromboembolisms. The American Society of Clinical Oncology practice guidelines recommend that all patients undergoing pelvic surgery for cancer should...
3.
Abdi M, Beswick P, Billinton A, Chambers L, Charlton A, Collins S, et al.
Bioorg Med Chem Lett
. 2010 Aug;
20(17):5080-4.
PMID: 20673717
A computational lead-hopping exercise identified compound 4 as a structurally distinct P2X(7) receptor antagonist. Structure-activity relationships (SAR) of a series of pyroglutamic acid amide analogues of 4 were investigated and...
4.
Beswick P, Billinton A, Chambers L, Dean D, Fonfria E, Gleave R, et al.
Bioorg Med Chem Lett
. 2010 Jun;
20(15):4653-6.
PMID: 20579878
Structure-activity relationships (SAR) of analogues of lead compound 1 were investigated and compound 16 was selected for further study in animal models of pain. Compound 16 was shown to be...
5.
Chambers L, Stevens A, Moses A, Michel A, Walter D, Davies D, et al.
Bioorg Med Chem Lett
. 2010 Apr;
20(10):3161-4.
PMID: 20399651
High-throughput screening identified compound 1 as a potent P2X(7) receptor antagonist suitable for lead optimisation. Structure-activity relationships (SAR) of a series of (1H-pyrazol-4-yl)acetamides were investigated and compound 32 was identified...
6.
Swarbrick M, Beswick P, Gleave R, Green R, Bingham S, Bountra C, et al.
Bioorg Med Chem Lett
. 2009 Jun;
19(15):4504-8.
PMID: 19520573
A novel series of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidine-based cyclooxygenase-2 (COX-2) inhibitors, which have a different arrangement of substituents compared to the more common 1,2-diarylheterocycle based molecules, have been discovered. For example, 2-(butyloxy)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine (47),...